Webinar: Optimizing Formulation Strategies for Poorly Soluble Compounds: Insights into Bioavailability Enhancement and Accelerated Development

With 70% of small molecule drug candidates classified as poorly soluble (BCS Class II and IV), achieving adequate absorption in the gastrointestinal (GI) tract remains a critical challenge in drug development. This webinar delves into effective formulation strategies to overcome these solubility and bioavailability hurdles.

Join us as we explore the latest advancements in bioavailability enhancement technologies, including hot melt extrusion (HME) and spray dried dispersion (SDD), which are gaining momentum in the industry. We'll discuss the critical factors to consider when selecting the optimal formulation approach during the late discovery and pre-clinical phases, emphasizing that no single solution fits all scenarios.

The session will include:

Register Now

Speakers:

Feng Zhang, Ph.D.

Associate Professor of Molecular Pharmaceutics and Drug Delivery

University of Texas at Austin

Hong Li, Ph.D.

VP of Formulation

BioDuro